The rocky road of limited immunosuppression for renal transplantation in African Americans

Transplantation

Volumn 83, Issue 3, 2007, Pages 267-269

  Braun, William E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; AFRICAN AMERICAN; ALLOIMMUNITY; BLOOD GROUP DUFFY SYSTEM; BLOOD GROUP LEWIS SYSTEM; CAUCASIAN; CHRONIC GRAFT REJECTION; DRUG BLOOD LEVEL; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NEPHROTOXICITY; NONHUMAN; NOTE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN FUNCTION; RACE DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VASCULITIS;

AFRICAN AMERICANS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 33846997851     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251654.84774.5a     Document Type: Note

References (44)

1. Isaacs R, Williams WW Jr, Ciancio G, et al. Issues and outcomes for ethnic kidney transplant recipients. CME Consultants; June 2006.
2. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343: 1545.
3. Gaston RS, Danovitch GM, Adams PL, et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775.
4. Epstein AM, Ayanian JZ, Keogh JH, et al. Racial disparities in access to renal transplantation- clinically appropriate or due to underuse or overuse? N Engl J Med. 2000; 343: 1537.
5. Kerman RH, Kimball PM, Van Buren CT, et al. Influence of race on crossmatch outcome and recipient eligibility for transplantation. Transplantation 1992; 53: 64.
6. Kerman RH, Kimball PM, Van Buren CT, et al. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991; 51: 338.
7. Hutchings A, Purcell WM, Benfield MR. Increased costimulatory responses in African-American kidney allograft recipients. Transplantation 2001; 71: 692.
8. 7a. Poggie ED, Clemente M, Hricik DE, Heeger PS. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006; 17: 564.
9. Suthanthiran M, Khanna A, Cukran D, et al. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 1998; 53: 639.
10. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999; 67: 882.
11. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated smallvessel vasculitis. Ann Intern Med 2005; 143: 621.
12. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular disease collaborative network. Kidney Int 1997; 51: 1188.
13. Pfaff WW, Howard RJ, Ireland J, Scornik J. The effect of Lewis antigen and race on kidney graft survival. Transplant Proc 1983; 15: 1139.
14. Mange KC, Prak EL, Kamoun M, et al. Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function. Kidney Int 2004; 66: 1187.
15. Organ Procurement and Transplantation Network, May 23, 2006. Personal communication.
16. Barger BO, Hudson SL, Shroyer TW, et al. Influence of race on renal allograft survival in the pre- and postcyclosporine era. Clin Transpl 1987; 217.
17. Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. Clin Transpl 1990; 447.
18. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995; 379.
19. Chertow GM, Milford EL. Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther 1997; 4: 40.
20. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 kidney transplant study group. Transplantation 1998; 65: 515.
21. Scantlebury V, Gjertson D, Eliasziw M, et al. Effect of HLA mismatch in African-Americans. Transplantation 1998; 65: 586.
22. Ojo AO, Port FK, Held PJ, et al. Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection. Kidney Int 1995; 48: 1592.
23. Light JA, Aquino AO, Ghasemian R, et al. Kidney transplants in African-Americans: Why are outcomes similar between races with living but not deceased donors? Am J Transplant. 2005; Suppl II: 413.
24. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366.
25. Meier-Kriesche HU, Kaza H, Palekar SS, et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509.
26. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005; 79: 716.
27. Podder H, Kahan BD. Individualization of immunosuppressive therapy: I. sirolimus improves outcomes in African-American renal transplant recipients. Transplant Proc 2005; 37: 3723.
28. Podder H, Podbielski J, Hussein I, et al. Sirolimus improves the twoyear outcome of renal allografts in African-American patients. Transpl Int 2001; 14: 135.
29. Lo A, Egidi MF, Gaber LW, et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004; 18: 53.
30. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. steroid withdrawal study group. Transplantation 1999; 68: 1865.
31. Hricik DE, Anton HA, Knauss TC, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189.
32. Hardinger KL, Stratta RJ, Egidi MF, et al. Renal allograft outcomes in African American versus caucasian transplant recipients in the tacrolimus era. Surgery 2001; 130: 738.
33. Hricik DE, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76: 938.
34. Gruber SA, West MS, Sillix DH, et al. Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients. Surgery 2005; 138: 772.
35. Anil Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5: 1976.
36. Boardman RE, Alloway RR, Alexander JW, et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005; 5: 356.
37. Hricik DE, Augustine JJ, Knauss TC, et al. Long-term graft outcomes after steroid withdrawl in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007; 83: 277.
38. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137: 364.
39. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006; 20: 10.
40. Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55: 51.
41. Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000; 70: 1240.
42. Siegal BR, Greenstein SM. Postrenal transplant compliance from the perspective of African-Americans, Hispanic-Americans, and Anglo-Americans. Adv Ren Replace Ther 1997; 4: 46.
43. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840.
44. Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2.